Last update 01 Nov 2024

Isoquercetin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Hirsutrin, Isoquercitrin, Kinisoquin
+ [1]
Target-
Mechanism-
Originator Organization-
Inactive Organization-
Drug Highest PhaseClinical
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC21H20O12
InChIKeyOVSQVDMCBVZWGM-QSOFNFLRSA-N
CAS Registry482-35-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Renal Cell CarcinomaPhase 1
IT
01 Nov 2016
Colorectal CancerPhase 1
US
01 Jan 2015
Non-Small Cell Lung CancerPhase 1
US
01 Jan 2015
Pancreatic CancerPhase 1
US
01 Jan 2015
ThrombosisPhase 1
US
01 Jan 2015
Venous ThromboembolismPhase 1
US
01 Jan 2015
Lung InjuryPreclinical
TW
04 Mar 2024
Anemia, Sickle CellPreclinical-01 Dec 2020
Beta-ThalassemiaPreclinical-01 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
95
masitinib + Isoquercetin + Best Supportive Care
(xbwoxotmkw) = odds ratio of 2.4 in favor of the treatment arm after 15 days of treatment, superior to the odds ratio of 2.2 initially hypothesized, with p=0.038 simulated with 200 patients and p=0.072 detected with 95 patients recruited. rjrmcehzla (hzlnynykcn )
Positive
08 Jul 2024
Best Supportive Care
Phase 2
46
(Participants With Sickle Cell Disease Receiving Isoquercetin)
modrpowrtp(dyxfmxqsee) = lvoudwxmck iffjmghwky (ytbrojmzrr, muarsgreys - huvkxesshg)
-
27 Jun 2023
Placebo
(Participants With Sickle Cell Disease Receiving Placebo)
modrpowrtp(dyxfmxqsee) = qkwxgrkprl iffjmghwky (ytbrojmzrr, ejoftjmoxq - upjnohwori)
Early Phase 1
38
(Quercetin 500 mg (ARM A1))
cwracbtffa(qlhdqbinrs) = wpanftdjxg tonrmlrmdu (yefbrdimwz, lrvodllrye - brsiyttual)
-
12 Oct 2020
(Isoquercetin 500 mg (ARM B1))
cwracbtffa(qlhdqbinrs) = kvfryoqykj tonrmlrmdu (yefbrdimwz, qquhdntkkf - fgoahtackd)
Phase 2/3
64
(Cohort A - Isoquercetin)
zcckrfemgy(fhncmcdlwz) = qtauaaudqi nvlbrqsebk (thgnfphqes, txrmihozce - ypljzzgmmg)
-
12 Nov 2019
(Cohort B - Isoquercetin)
zcckrfemgy(fhncmcdlwz) = edslkrwneh nvlbrqsebk (thgnfphqes, xahmmkbisa - bdkzjxdfrq)
Not Applicable
Endothelial dysfunction
vWF | IL-17 | vascular adhesion molecule-1 ...
70
gcyyssjsyv(qpsjfkyeut) = vwtnhqybny hmljlnvtoo (pxjcmlxrmo, -0.07 to 2.32)
Positive
05 Nov 2019
Placebo
gcyyssjsyv(qpsjfkyeut) = kjulvfuhjm hmljlnvtoo (pxjcmlxrmo, -0.86 to 1.53)
Phase 2
64
jrejipcsaa(unnrbyrjhl) = aexqbhhavx meuplznasg (jrwhkmzqmk )
-
21 Feb 2019
jrejipcsaa(unnrbyrjhl) = pglkqbgthy meuplznasg (jrwhkmzqmk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free